Monoclonal Antibodies Therapeutics Market Size Projected to Reach USD 1,057.91 Billion by 2034
The global monoclonal antibody therapeutics market is projected to grow from USD 304.52 billion in 2025 to approximately USD 1,057.91 billion by 2034, registering a CAGR of 14.84% over the forecast period.
Ottawa, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The global monoclonal antibody therapeutics market size was estimated at USD 265.17 billion in 2024 and is projected to reach approximately USD 1,057.91 billion by 2034, growing at a compound annual growth rate (CAGR) of 14.84%, according to a study by Towards Healthcare, a sister company of Precedence Research.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5490
Key Takeaways
- North America was dominant in the market in 2024.
- Asia Pacific is expected to grow fastest during 2025-2034 in the monoclonal antibodies therapeutics market.
- By type, the human mAb segment dominated the market in 2024.
- By type, the humanized mAb segment is expected to register the fastest growth in the studied years.
- By application, the cancer segment held a major share of the market in 2024.
- By application, the autoimmune disease segment is expected to grow at the fastest CAGR during 2025-2034.
- By distribution channel, the hospital pharmacy segment led the monoclonal antibodies therapeutics market in 2024.
- By distribution channel, the online pharmacy segment is expected to witness rapid expansion in the predicted timeframe.
Market Overview & Potential
These therapeutics are lab-produced proteins, which can accurately target specific molecules to treat diseases, such as cancer, autoimmune disorders, and infectious diseases. Furthermore, the monoclonal antibodies therapeutics market is fostering advancements in antibody engineering, including generating fully humanized antibodies, which have minimized immune responses and enhanced treatment outcomes. As well as researchers are also investigating innovative and optimized ways to deliver mAbs, likewise inhaled antibodies for respiratory diseases, to boost efficacy and patient convenience.
What are the Kry Growth Drivers Involved in the Market Expansion?
In the revolutionary era, the monoclonal antibodies therapeutics market is mainly propelled by the growing chronic disease cases, which are increasingly demanding targeted therapies. This demand further drives the development of more efficient and tailored treatment solutions. Besides this, ongoing major R&D investments from both government and private sectors are supporting the discovery and development of newer mAb-based therapies. A rise in innovations in genetic engineering and biotechnology is resulting in the emergence of novel therapeutics.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
What are the Drifts in the Monoclonal Antibodies Therapeutics Market?
Mainly involved growth factors in the respective market are the arising investment and collaboration among diverse organizations for the development of new approaches.
- In June 2025, Bio-Techne Corporation entered into a distribution agreement with the U.S. Pharmacopeia (USP) that allows the Company to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards with its analytical solutions.
- In December 2024, Indapta Therapeutics secured $22.5 million in funding to expand the clinical development of its lead candidate, IDP-023, an allogeneic g-NK (FcRγ-deficient natural killer) cell therapy naturally engineered to treat cancer and autoimmune diseases.
- In December 2024, Chennai-based Omexa Formulary Pvt Ltd planned to start a new manufacturing unit for monoclonal antibodies and formulation products with an investment of ₹95 crore.
What are Major Limitations in the Market?
There are certain challenges arising in the monoclonal antibodies therapeutics market, including a wider need for a cold chain for storage and transport, with other logistical complexities and expenses. For some mAb therapies, there may be a barrier in their injectable forms, like intravenous (IV) and subcutaneous (SC) administration, due to protein instability and the propensity to aggregate.
Regional Analysis
Monoclonal Antibodies Therapeutics Market Size, By Region (USD Billion)
| 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | |
| North America | 106.1 | 121.2 | 138.5 | 158.2 | 180.8 | 206.6 | 236.0 | 269.6 | 308.0 | 351.9 | 402.0 |
| Europe | 66.3 | 75.8 | 86.7 | 99.2 | 113.5 | 129.8 | 148.4 | 169.7 | 194.1 | 222.0 | 253.9 |
| Asia-Pacific | 53.0 | 61.5 | 71.3 | 82.7 | 95.9 | 111.2 | 128.9 | 149.5 | 173.3 | 200.8 | 232.7 |
| Latin America | 21.2 | 24.5 | 28.3 | 32.7 | 37.8 | 43.7 | 50.5 | 58.3 | 67.4 | 77.8 | 89.9 |
| Middle East & Africa | 18.6 | 21.5 | 24.8 | 28.7 | 33.2 | 38.4 | 44.4 | 51.3 | 59.4 | 68.6 | 79.3 |
Why did North America Dominate the Market in 2024?
In 2024, North America accounted for the biggest share of the monoclonal antibodies therapeutics market. This region’s strong healthcare system, highest healthcare spending, and advanced hospitals and specialty pharmacies are offering broader patient access and adoption of mAb therapies. Nowadays, the US is focusing on producing next-generation products, like antibody-drug conjugates, coupled with a stricter regulatory framework. This regulatory landscape is escalating the launch of new mAb drugs and biosimilars in the US and other major regions.
For this market,
- In November 2024, Laekna, Inc., a global biotech company, made a clinical collaboration with Eli Lilly and Company (Lilly), a global player in cardiometabolic health, to boost the development of LAE102, a novel ActRIIA mAb as a novel treatment for obesity.
What Made the Asia Pacific Grow Notably in the Market in 2024?
During 2025-2034, the Asia Pacific is anticipated to register rapid growth in the monoclonal antibodies therapeutics market. Across the ASAP, there is a growing cases of chronic and autoimmune diseases, like different cancers, rheumatoid arthritis, and multiple sclerosis, increasing demand for advanced, targeted treatments, such as monoclonal antibodies. Whereas, China, India, Singapore, and South Korea are accelerating investments in biomanufacturing, R&D, and other local progression of these therapeutics.
For instance,
- In December 2024, RAPT Therapeutics, Inc., a clinical-stage, immunology-based biopharmaceutical company, and Shanghai Jemincare Pharmaceutical Co., Ltd, a leading pharmaceutical company in China, partnered for JYB1904 (RAPT designation RPT904), a clinical-stage, half-life extended anti-immunoglobulin E (IgE) monoclonal antibody.
Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting
Segmental Insights
By type analysis
Monoclonal Antibodies Therapeutics Market Size, By Type (USD Billion)
| 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | |
| Human mAb | 145.8 | 168.1 | 193.7 | 223.3 | 257.4 | 296.6 | 341.8 | 394.0 | 454.0 | 523.3 | 603.0 |
| Humanized mAb | 66.3 | 75.8 | 86.7 | 99.2 | 113.5 | 129.8 | 148.4 | 169.7 | 194.1 | 222.0 | 253.9 |
| Chimeric mAb | 39.8 | 45.5 | 52.0 | 59.4 | 67.9 | 77.6 | 88.7 | 101.4 | 115.8 | 132.4 | 151.3 |
| Murine mAb | 13.3 | 15.1 | 17.3 | 19.7 | 22.5 | 25.7 | 29.3 | 33.5 | 38.2 | 43.6 | 49.7 |
The human mAb segment registered dominance in the monoclonal antibodies therapeutics market in 2024. Ongoing advances in genetic engineering, biotechnology, and protein engineering are supporting the wide range of applications of human mAb. Alongside, other approaches are currently being developed over the conventional hybridoma technology to merge phage display libraries, B-cell immortalization, and the use of transgenic mice to generate fully human antibodies.
On the other hand, the humanized mAb segment is estimated to grow rapidly in the studied years. The advantages of this type include minimized immunogenicity, enhanced effectiveness, and expanded safety as compared to older antibody types, resulting in greater demand for cancer, autoimmune, and infectious disease treatments. Nowadays, they have immense applications in immediate immunity against pathogens, particularly Dengue, HIV, and influenza, and are being executed as a new paradigm for vaccines and antiviral therapies.
By application analysis
In 2024, the cancer segment captured the dominating share of the market. The increasing development of targeted and customized therapies is widely impacting their adoption in the growing cancer cases. Ongoing new approaches involve the use of these mAbs integrated with nanoscale delivery systems to expand their targeted delivery and therapeutic efficacy. Additionally, this supports boosting stability, controlling release, and increasing penetration into the tumor. Also, the huge utilization of mAbs by coupling with other treatments, especially chemotherapy, hormone therapy, and other immunotherapies, is assisting in raising survival rates.
And, the autoimmune disease segment is predicted to expand rapidly during the forecast period. The segment has been adopting newer mAbs that are established to target two or more molecules simultaneously, augmenting their therapeutic potential in difficult autoimmune conditions by blocking multiple signaling pathways. Although researchers are working to target membrane-bound receptors and other cellular components implicated in autoimmune pathogenesis, with providing innovative treatment plans. The contribution of bi-specific and multi-specific antibodies targeting multiple inflammatory pathways, and the development of more potent antibody-drug conjugates (ADCs), are escalating convenience and efficiency.
By distribution channel analysis
The hospital pharmacy segment captured the largest revenue share of the monoclonal antibodies therapeutics market in 2024. A prominent driver of this segment expansion is the participation of pharmacists, who facilitate vital clinical and pharmacological expertise for required dosing, formulation, and drug monitoring, which is important for these specialized treatments. Hospital pharmacies possess a favourable environment, cold storage, infusion centers, and well-trained personnel, which are essential for handling and administering injectable biologics like mAbs.
Whereas, the online pharmacy segment will register the fastest growth during 2025-2034. Leveraging telemedicine approaches is widely supported to enhance accessibility of mAb therapeutics, mainly in cost-sensitive markets or for patients with mobility concerns. Eventually, these online pharmacies act as a valuable, complementary channel for ongoing and long-term care of chronic issues. The wider and developing trend regarding decentralized healthcare and outpatient treatment favors online pharmacies as convenient, accessible points for managing various health concerns.
Get the latest insights on healthcare industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership
Recent Developments
- In August 2025, Intas Pharmaceuticals unveiled HETRONIFLY™ (Serplulimab), India's first novel immunotherapy for advanced small-cell lung cancer.
- In July 2025, Infinimmune, a biotechnology company, launched GLIMPSE-1 AI model trained exclusively on human antibody sequences for advanced therapeutic engineering.
- In July 2025, Twist Bioscience expanded its in vivo antibody discovery services with the launch of a humanized transgenic mouse model.
Monoclonal Antibodies Therapeutics Market Key Players
- Pfizer Inc.
- Novartis AG
- Bayer AG
- Sanofi
- F.Hoffmann-La Roche Ltd
- Eli Lilly and Company
- Merck KGaA
- GSK plc.
- AbbVie Inc.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- AstraZeneca
- AbCellera Biologics Inc.
- Molecular Depot LLC
- DAIICHI SANKYO COMPANY, LIMITED.
- Abbott
- Biogen
- Thermo Fisher Scientific, Inc.
- Cell Signaling Technology, Inc
- Intas Pharmaceuticals Ltd.
- Avantor Inc.
- UCB S.A.
- Merus N.V.
- GENEXTGENOMICS.COM
- Biogenuix
Browse More Insights of Towards Healthcare:
The global monoclonal antibodies market in veterinary health was valued at USD 1.23 billion in 2024 and grew to USD 1.45 billion in 2025. It is projected to reach approximately USD 6 billion by 2034, expanding at a robust CAGR of 17.13% between 2025 and 2034.
The gene editing therapeutics market is witnessing rapid global advancements, with revenue expected to scale into the hundreds of millions between 2025 and 2034.
The global mRNA therapeutics CDMO market stood at USD 4.62 billion in 2024 and grew to USD 5.15 billion in 2025. By 2034, the market is anticipated to reach around USD 13.63 billion, growing at a CAGR of 11.37% over the forecast period.
The global single-cell biotherapeutics market is on an upward trajectory, projected to achieve substantial revenue growth, potentially reaching hundreds of millions between 2025 and 2034.
The global molecule therapeutics market is emerging as a high-potential sector, poised for strong growth throughout 2024–2034.
The global non-small cell lung cancer therapeutics market was valued at USD 21.5 billion in 2024 and increased to USD 24.24 billion in 2025. It is expected to reach around USD 71.2 billion by 2034, expanding at a CAGR of 12.74% from 2025 to 2034.
The global digital therapeutics market grew from USD 7.7 billion in 2024 to USD 9.84 billion in 2025 and is projected to reach approximately USD 90.83 billion by 2034, with a striking CAGR of 27.8% during the forecast period.
The global protein therapeutics market was valued at USD 375.3 billion in 2024, growing to USD 401.89 billion in 2025. By 2034, it is expected to reach USD 740.07 billion, expanding at a CAGR of 7.08% from 2025 to 2034.
The global digital psychotherapeutics market rose from USD 1.69 billion in 2024 to USD 2.17 billion in 2025 and is anticipated to reach USD 20.66 billion by 2034, growing at a CAGR of 28.24% over the forecast period.
The global antisense and RNAi therapeutics market is expected to grow from USD 7.38 billion in 2025 to USD 35.63 billion by 2034, reflecting a CAGR of 19.12% throughout the forecast period.
Segments Covered in The Report
By Type
- Human mAb
- Humanized mAb
- Chimeric mAb
- Murine mAb
By Application
- Cancer
- Autoimmune Diseases
- Others
By Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
By Region
- North America
- U.S.
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/price/5490
Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web: https://www.towardshealthcare.com
Our Trusted Data Partners
Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
